Investment Rating - The report suggests a positive investment outlook for the beauty and personal care sector, recommending a "buy" rating for high-growth companies with strong brand power and innovative product offerings [2][3]. Core Insights - The beauty and personal care sector is experiencing a slow recovery, with significant differentiation among sub-sectors. Personal care products and innovative channels continue to perform strongly, while the cosmetics sector shows signs of slowing growth due to domestic brand competition [1][2][3]. - For 2026, the overall beauty and personal care market is expected to remain stable, but further differentiation among companies is anticipated. The report emphasizes the importance of selecting high-growth targets with product and channel innovations [2][3]. Summary by Sections Overall Market Performance - In the first three quarters of 2025, the beauty and personal care sector saw revenues and net profits increase by 2.7% and 4.9% respectively, with personal care outperforming cosmetics and medical aesthetics [12][31]. - The cosmetics sector experienced a slight decline in revenue, with a 0.4% decrease year-on-year, while net profit fell by 2.3% [31][33]. Personal Care Sector - The personal care segment achieved revenues of 52 billion yuan and net profits of 5 billion yuan, reflecting a year-on-year increase of 33.7% and 5.7% respectively. The third quarter alone saw a revenue increase of 41.1% [12][16]. - Companies like Ruoyuchen reported impressive growth, with a 123% increase in revenue and a 73% increase in net profit in the third quarter [12][28]. Cosmetics Sector - The cosmetics sector's revenue for the first three quarters was 308 billion yuan, with a net profit of 30 billion yuan, showing a decline of 0.4% and 2.3% respectively. The third quarter saw a revenue drop of 0.5% but a significant profit increase of 50.8% [12][31]. - The report highlights the importance of individual company strategies and product life cycles in determining performance within the cosmetics sector [13][48]. Medical Aesthetics Sector - The medical aesthetics segment reported revenues of 75 billion yuan and net profits of 27 billion yuan, with a slight revenue decline of 0.7% but a profit increase of 14.5% year-on-year [12][52]. - The third quarter saw a revenue increase of 1.8% and a remarkable profit growth of 96.6%, although underlying performance was affected by increased competition and integration challenges [52][56]. Investment Recommendations - The report recommends focusing on high-growth companies with strong brand power, such as Ruoyuchen, Shangmei, and Maogeping, as well as companies with stable fundamentals and potential for marginal improvement like Dengkang Oral and Shanghai Jahwa [2][3]. - It also suggests monitoring companies that are expected to reach a turning point, such as Runben and Jinjian Biological, which may present investment opportunities [2][3].

Core Viewpoint - The 2025 China International Import Expo (CIIE) saw a lower participation rate from leading beauty companies, reflecting a trend of market growth slowing down and companies opting for cost-saving measures while still seeking innovative product development and localized strategies [1][2]. Group 1: Product Innovation and Localization - New products are taking center stage, with a focus on localized customization being a key theme among multinational companies [2][4]. - Shiseido's medical beauty brand RQ PYOLOGY showcased a new project developed in collaboration with local institutions, emphasizing the importance of local partnerships in innovation [2][4]. - The introduction of a unique "skin rhythm" evaluation system by RQ PYOLOGY aims to provide precise skin condition analysis, highlighting a shift towards research-driven, localized product strategies [4][20]. Group 2: Mature Brand Strategy - Multinational companies are increasingly favoring the introduction of mature brands into the Chinese market as a pragmatic response to slowing growth, leveraging established supply chains and faster market entry [9][11]. - Shiseido's fragrance and beauty brand Serge Lutens made its debut at the expo, with plans for formal entry into the Chinese market next year [11][13]. - The professional skincare sector is also witnessing a wave of established brands entering the market, such as Amorepacific's Aestheline and L'Oréal's Dr.G, indicating a trend towards stability and reliability in brand offerings [11][13]. Group 3: Technological Innovation - Technology is redefining competitive boundaries, with brands like Kosé utilizing quantum computing to enhance product formulation efficiency [17][20]. - L'Oréal released a white paper on PDRN (Polydeoxyribonucleotide) applications in skincare, showcasing its potential in anti-aging and skin longevity [20][22]. - Chinese companies like Huaxi Bio are also responding to global anti-aging trends with systematic research on ECM (extracellular matrix) solutions, indicating a robust focus on scientific innovation [22][24]. Group 4: Market Trends and Consumer Focus - Beauty brands are shifting from aggressive marketing tactics to enhancing user experience, focusing on product efficacy and consumer needs [9][20]. - The emphasis on practical innovation reflects a broader industry consensus that growth is returning to a more rational and realistic trajectory, prioritizing verifiable product effectiveness over mere concepts [24].

Core Viewpoint - Huaxi Biological's stock price has shown a slight decline this year, with recent trading indicating a downward trend, while the company continues to maintain a diverse business model in the biotechnology sector [2][3]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [2]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end users [2]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed over the past three years [3]. Stock Performance - As of November 10, Huaxi Biological's stock price was 50.79 yuan per share, with a market capitalization of 24.464 billion yuan. The stock has decreased by 0.27% this year, with a 4.39% drop over the last five trading days [1][2]. - The company experienced a net inflow of main funds amounting to 2.5905 million yuan, with large orders accounting for 24.19% of total purchases [1]. Shareholder Information - As of October 31, the number of Huaxi Biological's shareholders was 30,600, an increase of 0.86% from the previous period. The average circulating shares per person decreased by 0.85% to 15,749 shares [2]. - The top ten circulating shareholders include several ETFs, with notable reductions in holdings for major funds such as E Fund and Huaxia [3].

- The report predicts the adjustment of sample stocks for the CSI 300, CSI 500, and STAR 50 indices in December 2025[1][6] - The CSI 300 Index selects companies with good operating conditions, no violations, no major financial report issues, and no significant stock price anomalies[7] - The CSI 500 Index excludes CSI 300 sample stocks and the top 300 stocks by average market value, selecting companies with good operating conditions and no major issues[9][10] - The STAR 50 Index selects companies listed on the STAR Market with good operating conditions, no violations, and no major financial report issues[13] - The report provides detailed predictions for stocks to be included and excluded from each index based on average market value and average trading volume[8][11][14]

Investment Rating - The investment rating for the beauty and personal care industry is "Positive" (maintained) [3] Core Viewpoints - The beauty market in China showed steady performance in Q1-Q3 2025, with retail sales of cosmetics growing by 3.9% year-on-year, surpassing the overall retail sales growth of consumer goods at 3.3% [4][5] - The high-end segment is expected to outperform the mass market, with projected CAGR for high-end skincare and makeup at 9.6% and 10.8% respectively from 2023 to 2028, compared to 8.2% and 6.7% for the mass market [6] Summary by Sections Market Performance - In Q1-Q3 2025, the beauty market maintained stable demand, with monthly retail sales growth fluctuating, peaking at 8.6% in September [4][5] - The personal care segment performed well, with revenue reaching 52.3 billion yuan, a year-on-year increase of 33.7% [16] Segment Analysis - Cosmetics segment revenue was 299.9 billion yuan, with a slight increase of 0.02%, while net profit decreased by 2.5% [16] - The medical beauty segment saw revenue of 74.9 billion yuan, a decrease of 0.7%, but net profit increased by 14.5% [16] - The personal care segment's revenue growth was driven by product innovation and expansion, with notable performances from companies like RuBen and RYTHM [16] Brand Competition - The competitive landscape is stable, with domestic brands like Proya and Han Shu gaining market share, particularly in platforms like Tmall and Douyin [11][12] - The report highlights the increasing strength of domestic brands due to their brand power and local advantages [12]

Core Insights - The retail industry is experiencing a shift from value preservation to emotional value, with a focus on high-growth segments for investment opportunities [5][28] - The report maintains a positive outlook on the retail sector, emphasizing the importance of consumer insights and differentiated product offerings [5][28] Retail Market Overview - The retail index reported a slight increase of 0.31% during the week of November 3 to November 7, 2025, underperforming the Shanghai Composite Index, which rose by 1.08% [7][16] - Year-to-date, the retail index has increased by 4.20%, lagging behind the Shanghai Composite Index's 19.27% growth [16][20] Investment Strategy for 2026 - The investment strategy highlights four main themes: 1. **Gold and Jewelry**: Focus on high-end and fashionable gold segments, with recommendations for brands like Lao Pu Gold and Chao Hong Ji [5][48] 2. **Retail E-commerce**: Emphasize the transformation of offline retail to enhance service and experience, with key players like Yonghui Supermarket and Ai Ying Shi [5][48] 3. **Cosmetics**: Target domestic brands that capture emotional value and innovate on safety ingredients, recommending brands like Juzi Biological and Pechoin [5][49] 4. **Medical Aesthetics**: Focus on differentiated product manufacturers and expanding medical institutions, with recommendations for brands like Ai Mei Ke and Ke Di-B [5][49] Sector Performance - The jewelry sector is undergoing significant changes due to rising gold prices and a decline in traditional wedding markets, leading to the emergence of brands with strong consumer insights [5][29] - The cosmetics sector is seeing a rise in domestic brands leveraging cultural roots and emotional value to capture market share [5][41] Company-Specific Insights - **Chao Hong Ji**: Reported a revenue increase of 28.4% year-on-year for the first three quarters of 2025, with a notable performance in Q3 [54] - **Yonghui Supermarket**: Experienced a revenue decline of 22.2% year-on-year for the first three quarters of 2025, but is undergoing significant transformation [50] - **Juzi Biological**: Achieved a revenue growth of 21.7% year-on-year for the first half of 2025, focusing on collagen products [50]

Core Viewpoint - The eighth China International Import Expo has showcased Huaxi Biological's innovative solutions in anti-aging based on extracellular matrix (ECM) science, highlighting China's strength in life sciences innovation [1] Group 1: ECM Scientific Layout - Huaxi Biological maintains a systematic scientific layout of ECM, aligning with global life science frontiers, with ECM changes recognized as a major aging marker by 2025 [3] - The company actively participates in ECM research, focusing on key components like hyaluronic acid and collagen, transitioning from a "single substance era" to a "system structure era" in anti-aging research [3] - Huaxi Biological's research system integrates glycomics and cell biology, utilizing a 30 billion-level molecular database and AI R&D platform for multi-scale research and engineering applications [3] Group 2: Global Research and Industry Application - The company's active substances are widely adopted by global Fortune 500 companies and top research institutions, contributing to ECM signal communication and regeneration mechanism studies [5] Group 3: Innovation and Manufacturing Capabilities - At the Import Expo, Huaxi Biological showcased innovative products derived from ECM research, leveraging China's manufacturing capabilities and a leading pilot transformation platform with 64 pilot production lines [6] - The company has received multiple domestic and international awards for its raw material research, exemplifying the effective transformation of cutting-edge research into market results [9] Group 4: Transition from Manufacturing to Standard Setting - Huaxi Biological is transitioning from "technology output" to "standard leadership," establishing a global intellectual property protection network through PCT patents in over 30 countries [9] - The company plans to build a regional center in Europe for "nearshore manufacturing" to quickly respond to global market demands [9] Group 5: Product Development and Medical Applications - The company's product lines, such as Runbaiyan, demonstrate the ability to rebuild healthy ECM networks, while Huaxi Dangkang nutrition products reflect a systemic anti-aging approach [10] - Huaxi Biological has obtained 11 Class III medical device certificates for aesthetic injection products, with the latest technology capable of rejuvenating skin by restoring ECM structure [10] Group 6: Milestone Achievements - Huaxi Biological has established the international standard for hyaluronic acid (ISO 22718), breaking the monopoly of Western companies on bioactive substance standards, marking a significant shift in the company's role [12] - The company aims to enhance China's influence in global life sciences through leading-edge research and industry ecosystem construction, signaling the start of a new cycle in systemic anti-aging [12]

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. (hereinafter referred to as "Marubi") has been warned by the Guangdong Securities Regulatory Bureau due to irregularities in financial accounting and management of raised funds, indicating significant internal management shortcomings [1][2]. Financial Irregularities - Marubi's financial accounting issues include inaccurate revenue recognition, incorrect construction project accounting, and erroneous reporting of related accounting items [1]. - The company used raised funds for cash management without proper disclosure of investment returns and related information [1]. - Following the regulatory warning, Marubi's chairman, secretary of the board, and CFO received warning letters from the regulatory authority [1]. Financial Performance - In the first half of 2025, Marubi's adjusted revenue was 1.765 billion yuan, a decrease of 4.5468 million yuan compared to previous adjustments, while the net profit attributable to shareholders was 174 million yuan, down by 11.3297 million yuan [2]. - For Q3 2025, Marubi reported revenue of 686 million yuan, a year-on-year increase of 14.28%, and a net profit of 69.4816 million yuan, up 21.16% [4]. - In the first three quarters of 2025, the company achieved revenue of 2.45 billion yuan, a growth of 25.51%, with a net profit of 244 million yuan, increasing by 2.13% [4]. Market Position and Competition - Marubi's main brand, Marubi, is positioned in the mid-to-high-end market, contributing 2.055 billion yuan to the company's total revenue of 2.97 billion yuan in 2024, accounting for 69.24% [4]. - Compared to competitors like Proya and Shiseido, Marubi faces challenges due to its mid-to-high-end pricing strategy and a smaller market size for eye creams [5]. - The company has been slower in transitioning to online sales channels compared to peers, which may hinder its competitive edge [5]. R&D Investment - In the first half of 2025, Marubi's R&D expenses were 39.9648 million yuan, representing 2.26% of total revenue, which is in line with industry averages but lower than leading competitors [6]. - The company aims to transition to a biotechnology-focused beauty brand, but its current R&D investment does not meet the necessary levels for such a transformation [6]. Future Outlook - The company's future development hinges on rebuilding trust in corporate governance and internal controls, enhancing R&D capabilities, and creating new growth engines to satisfy investors [6].

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]